Tamoxifen (Standard)

[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. [Content Brief]

[2]. Hawariah A, et al. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. [Content Brief]

[3]. Jun Nagai, et al. Hyperactivity with Disrupted Attention by Activation of an Astrocyte Synaptogenic Cue. Cell. 2019 May 16;177(5):1280-1292.e20. [Content Brief]

[4]. Zhao R, et al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. [Content Brief]

[5]. Kedjouar B, et al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279(32):34048-61. [Content Brief]

[6]. Feil S, et, al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. [Content Brief]

[7]. Laura Cooper, et al. Screening and Reverse-Engineering of Estrogen Receptor Ligands as Potent Pan-Filovirus Inhibitors. J Med Chem. 2020 Sep 4. [Content Brief]

[8]. El-Beshbishy HA. Hepatoprotective effect of green tea (Camellia sinensis) extract against tamoxifen-induced liver injury in rats. J Biochem Mol Biol. 2005 Sep 30;38(5):563-70. [Content Brief]

[9]. El-Beshbishy H A. The effect of dimethyl dimethoxy biphenyl dicarboxylate (DDB) against tamoxifen-induced liver injury in rats: DDB use is curative or protective[J]. BMB Reports, 2005, 38(3): 300-306. [Content Brief]

[10]. Buchanan C M, et al. Pharmacokinetics of tamoxifen after intravenous and oral dosing of tamoxifen–hydroxybutenyl-β-cyclodextrin formulations[J]. Journal of pharmaceutical sciences, 2007, 96(3): 644-660.